

COVID-19 COMPLICATIONS AND LONG TERM EFFECTS OF COVID-19 IN CHILDREN

Oscar G. Gomez, MD, PhD
Associate Professor and Chief
Division of Pediatric Infectious Diseases


May 10th, 2022

Jacobs School of Medicine and Biomedical Sciences | UB MD | PEDIATRICS




Outline

- Pulmonary
- Multisystem Inflammatory Syndrome in children associated with COVID-19 (MIS-C)
- Cardiovascular
- Neurological
- Other
- Post COVID-19 vs long COVID



Clinical Manifestations of COVID-19




Conditions associated with increased risk of severe COVID-19 in children

- Diabetes
- Hypertension
- Cardiac disease
- Chronic lung disease
- Cerebrovascular disease
- Chronic kidney disease
- Immunosuppression
- Cancer
- Obesity
- Asthma



WHO, 2020; CDC, 2022

Severity of illness in children with COVID-19



Souza et al., 2020

Pulmonary Manifestations & Complications




Pulmonary Manifestations & Complications

Clinical stages of COVID-19 Pulmonary disease:

- Early stage: edema, epithelial damage, and inflammation of capillaries and endothelium (day 0-1)
- Exudative diffuse alveolar damage stage (days 1-7)
- Organizing pneumonia stage (1 week to several weeks)
- The fibrotic stage (weeks to months)


Bösmüller, February 2021

Chest CT Features Associated With Mild to Moderate COVID-19 Pneumonia



Kunhua et al., 2020


Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia



Kunhua et al., 2020

1
3

Therapies for COVID-19



1
4

Anti-SARS-CoV-2 monoclonal antibodies with Emergency Use Authorizations from FDA :

- **Tixagevimab co-packaged with cilgavimab**
Indicated for pre-exposure prophylaxis
- **Sotrovimab**
Indicated for post-exposure prophylaxis.
- **Bebtelovimab**
Indicated for post-exposure prophylaxis.

1
5

Antiviral Drugs in development

Remdesivir

- Nucleoside analogue
- Intravenous remdesivir is approved by the FDA for the treatment of COVID-19 in adult and pediatric patients (aged ≥12 years and weighing ≥40 kg).
- It is approved for the treatment of mild to moderate COVID-19 in high-risk, nonhospitalized patients (i.e., a 3-day course initiated within 7 days of symptom onset) and for the treatment of hospitalized patients with COVID-19 (i.e., a 5-day course)

1
6

Antiviral Drugs in development

Nirmatrelvir-ritonavir

It's a protease inhibitor combination

- FDA EUA for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 yo and older weighing at least 40 kg) with positive results of SARS-CoV-2 and who are at high risk for progression to severe COVID-19, including hospitalization or death


1
7

Antiviral Drugs in development


Molnupiravir

- It's a pyrimidine ribonucleoside analog that inhibits RdRp of SARS-CoV-2 to induce RNA mutagenesis
- FDA EUA for the treatment of mild-to-moderate COVID19 in adults with positive results of direct SARS-CoV-2 who are at high risk for progression to severe COVID-19, including hospitalization or death
- No authorized for patient <18 year of age

Genomic Organization of SARS-CoV-2



Multisystem inflammatory syndrome in children (MIS-C)



Multisystem inflammatory syndrome in children (MIS-C)

Case definition for MIS-C:

•An individual aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); AND

•No alternative plausible diagnoses; AND

•Positive for current or recent SARS-CoV-2 (COVID-19) infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms.

CDC, 2022

Common signs and symptoms of MIS-C

- Kawasaki disease-like features
- Gastrointestinal: abdominal pain, diarrhea, nausea/vomiting
- Toxic shock syndrome-like features with hemodynamic instability and poor heart function
- Cytokine storm/macrophage activation or hyperinflammatory features.
- Thrombosis or acute kidney injury
- Shortness of breath suggestive of congestive heart failure or pulmonary embolism

CDC, 2022



Blatz et al., 2021; Pessoa et al., 2021

Recommended testing for MIS-C

- COVID-19 testing:
 - RT-PCR assay
 - Serologic testing
- Expanded laboratory tests including pro-BNP, triglycerides, creatine kinase, amylase, blood and urine culture, D-dimer, prothrombin time/partial thromboplastin time (PT/PTT), INR, CRP, ferritin, LDH, comprehensive metabolic panel, and fibrinogen
- Chest radiograph, EKG, Echo and troponin. If abnormal, consult pediatric cardiology and consider additional diagnostic testing for myocardial injury

CDC, 2022

Common laboratory findings in MIS-C

- An abnormal level of inflammatory markers in the blood, including
 - Elevated ESR/CRP
 - Elevated ferritin
 - Elevated LDH
- Lymphopenia <1000,
- Thrombocytopenia <150,000, neutrophilia.
- Elevated B-type natriuretic peptide (BNP) or NT-proBNP (pro-BNP),
- Hyponatremia
- Elevated D-dimers

CDC, 2022

Myocarditis and Pericarditis after mRNA COVID-19 Vaccines Among Adolescents and Young Adults

- Cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (mRNA SARS-CoV2 SP). This was not observed after receipt of the adenovirus-based COVID-19 Vaccine
- Reported cases have occurred predominantly in male adolescents and young adults 16 years of age and older
- Onset was typically within several days after mRNA COVID-19 vaccination
- Cases have occurred more often after the second dose than the first dose

Myocarditis and Pericarditis after mRNA COVID-19 Vaccines Among Adolescents and Young Adults

- Clinical manifestations: acute chest pain, shortness of breath, or palpitations. In this younger population, coronary events are less likely to be a source of these symptoms.
- Evaluation: ECG, troponin level, and inflammatory markers (C-reactive protein, procalcitonin, erythrocyte sedimentation rate).
- For suspected cases, consider consultation with cardiology for assistance with cardiac evaluation and management. Evaluation and management may vary depending on the patient age, clinical presentation, potential causes

Long-Term Cardiovascular Outcomes of COVID-19

- In a cohort of patients who survived the first 30 days after COVID-19 diagnosis, risk of incident cardiovascular disease was increased over the ensuing 12 months
- Population burdens of heart failure and atrial fibrillation were particularly increased among COVID-19 patients
- For all cardiovascular diagnoses, risk increased with greater severity of the acute infection


SARS-CoV-2 is associated with changes in brain structure

- Greater reduction in grey matter thickness and tissue-contrast in the orbitofrontal cortex and parahippocampal gyrus,
- Greater changes in markers of tissue damage in regions functionally-connected to the primary olfactory cortex
- Greater reduction in global brain size.

Douaud et al., 2022


Jacobs School of Medicine and Biomedical Sciences University at Buffalo UBI MD PEDIATRICS 40

Differences in grey matter thickness and mean diffusivity changes




Jacobs School of Medicine and Biomedical Sciences University at Buffalo UBI MD PEDIATRICS 41

Reduction in grey matter thickness and intensity contrast



Jacobs School of Medicine and Biomedical Sciences University at Buffalo UBI MD PEDIATRICS 42

Post-COVID-19 conditions google searches



Post-COVID-19 conditions vs Long COVID-19

- Common symptoms include:
 - Fatigue,
 - Shortness of breath,
 - Cognitive dysfunction
- Symptoms may be:
 - New onset, following initial recovery from an acute COVID-19 episode
 - Persist from the initial illness
 - Symptoms may also fluctuate or relapse over time

Post-COVID-19 conditions

- Almost 10% of children aged 2-11 years and 13% aged 12-16 years reported one or more lingering symptoms 5 weeks after COVID-19 infection
- Another study found that 25% of hospitalized children surveyed after discharge reported symptoms more than 5 months later
- A national survey in the Netherlands showed that among 89 children suspected of having long COVID, 18% were admitted to the hospital due to their long-term symptoms

Brackel, 2021; Osmanov, 2022
